Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VICL

Vical (VICL) Stock Price, News & Analysis

Vical logo

About Vical Stock (NASDAQ:VICL)

Key Stats

Today's Range
N/A
50-Day Range
$0.68
$3.15
52-Week Range
N/A
Volume
35,024 shs
Average Volume
1.44 million shs
Market Capitalization
$21.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive VICL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VICL Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
See More Headlines

VICL Stock Analysis - Frequently Asked Questions

Vical Incorporated (NASDAQ:VICL) released its quarterly earnings data on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The biotechnology company earned $0.12 million during the quarter, compared to analyst estimates of $0.04 million. Vical had a negative trailing twelve-month return on equity of 29.46% and a negative net margin of 1,002.10%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vical investors own include Caladrius Biosciences (CLBS), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA).

Company Calendar

Last Earnings
2/19/2019
Today
10/19/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VICL
CIK
819050
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.25 million
Net Margins
-1,002.10%
Pretax Margin
N/A
Return on Equity
-29.46%
Return on Assets
-27.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
36.84
Quick Ratio
36.84

Sales & Book Value

Annual Sales
$1.62 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.82 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
22,840,000
Free Float
N/A
Market Cap
$21.01 million
Optionable
Not Optionable
Beta
0.32
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:VICL) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners